Alesia sells BSX 12.69: Medtronicâs Pacemaker Sales Likely To Get A Boost From Positive MINERVA Trial Results
and Boston Scientific (NYSE:BSX). We believe that the aforementioned impressive trial results could help improve market sentiment in favor of Medtronicâs pacemaker products and drive sales going forward. We also expect new products such as the Advisa MRI ... ...
47 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home